10-Q: Denali Therapeutics Reports Third Quarter 2024 Results, Advances Pipeline

Denali Therapeutics reported its third quarter 2024 financial results, highlighting progress in its clinical programs and strategic initiatives.

Summary

• Denali Therapeutics reported a net loss of $107.2 million for the third quarter of 2024, compared to a net loss of $99.4 million for the same period in 2023.
• The company's collaboration revenue was $0 for the third quarter of 2024, compared to $1.3 million in the third quarter of 2023.
• Research and development expenses increased to $98.2 million in the third quarter of 2024 from $89.7 million in the third quarter of 2023.
• General and administrative expenses decreased slightly to $24.9 million in the third quarter of 2024 from $25.3 million in the third quarter of 2023.
• For the nine months ended September 30, 2024, Denali reported a net loss of $308.0 million, compared to a net loss of $25.8 million for the same period in 2023.
• Collaboration revenue for the nine months ended September 30, 2024 was $0, compared to $330.5 million for the same period in 2023.
• Research and development expenses for the nine months ended September 30, 2024 were $296.7 million, compared to $316.1 million for the same period in 2023.
• General and administrative expenses for the nine months ended September 30, 2024 were $75.4 million, compared to $78.6 million for the same period in 2023.
• The company recognized a gain of $14.5 million from the divestiture of its small molecule programs during the nine months ended September 30, 2024.
• As of September 30, 2024, Denali had cash, cash equivalents, and marketable securities totaling $1.28 billion.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in the pipeline and a strong cash position, the increased net loss and clinical trial setbacks temper the overall sentiment. The strategic shift towards TV-enabled platforms is a positive, but the termination of the Biogen license for the ATV:Abeta program is a setback.

Positives

• The company is progressing towards a BLA filing for tividenofusp alfa, indicating potential for near-term regulatory approval.
• Positive preliminary data from the DNL126 study suggests potential for a new treatment for MPS IIIA.
• The successful private placement significantly strengthened the company's financial position.
• The collaboration agreement for BIIB122/DNL151 provides funding and shared risk for a key clinical program.
• The return of rights to the ATV:Abeta program gives Denali full control over its future development.

Negatives

• The company experienced a significant decrease in collaboration revenue compared to the same periods in the previous year.
• The net loss for the nine months ended September 30, 2024, was significantly higher than the same period in 2023.
• The Phase 2 HIMALAYA study for SAR443820/DNL788 in ALS did not meet its primary endpoint.
• Sanofi discontinued the K2 Phase 2 study for SAR443820/DNL788 in multiple sclerosis due to not meeting primary and key secondary endpoints.

Risks

• The company is subject to risks associated with clinical trials, including delays, adverse events, and failure to demonstrate efficacy.
• The company is dependent on third-party manufacturers and suppliers, which could lead to supply chain issues.
• The company faces competition from other pharmaceutical and biotechnology companies.
• The company's intellectual property may be challenged or infringed upon.
• The company's financial performance is subject to market volatility and economic conditions.

Future Outlook

Denali plans to file a BLA for accelerated approval of tividenofusp alfa in early 2025 and continues to advance its other clinical programs. The company also intends to expand its manufacturing capabilities.

Management Comments

• The company plans to file a BLA for accelerated approval for tividenofusp alpha (DNL310) for the treatment of MPS II (Hunter syndrome), based on the outcome of a recent successful meeting with the Center for Drug Evaluation and Research (CDER) division of the FDA.
• Based on discussions with CDER, we will include preclinical and clinical data on biomarkers (CSF HS and neurofilament light (NfL)) and safety in the BLA for tividenofusp alfa as a treatment of MPS II and intend to submit the BLA under the accelerated approval pathway in early 2025.
• Based on the preliminary Phase 1/2 results and a positive regulatory environment, we recently expanded the study and continue to assess the development plans including an accelerated approval path.

Industry Context

The announcement reflects the ongoing challenges and opportunities in the development of treatments for neurodegenerative and lysosomal storage diseases. The company's focus on biomarker-driven development and BBB-crossing technology aligns with current industry trends.

Comparison to Industry Standards

• Denali's approach to neurodegenerative diseases, focusing on genetically validated targets and brain delivery, is consistent with the industry's move towards precision medicine.
• The company's use of biomarkers to inform dose selection and assess clinical activity is in line with best practices in drug development.
• The company's collaboration strategy with larger pharmaceutical companies like Biogen, Sanofi, and Takeda is a common approach for biotech companies to share risk and resources.
• The company's decision to divest its preclinical small molecule portfolio to focus on TV-enabled platforms reflects a strategic shift towards more promising technologies.
• The company's cash position of $1.28 billion is relatively strong compared to other clinical-stage biotech companies, providing a runway for continued development.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but encouraged by the progress in clinical programs and the strong cash position.
• Employees may be affected by the strategic shift and the divestiture of the small molecule programs.
• Patients with neurodegenerative and lysosomal storage diseases may benefit from the company's ongoing research and development efforts.
• Collaborators may be impacted by the changes in the company's strategy and the termination of the Biogen license for the ATV:Abeta program.

Next Steps

• File a BLA for accelerated approval of tividenofusp alfa (DNL310) for MPS II (Hunter syndrome) in early 2025.
• Continue enrollment in the global Phase 2/3 COMPASS study for tividenofusp alfa.
• Continue screening of participants for the global Phase 2a study to evaluate safety and biomarkers associated with BIIB122/DNL151 in participants with Parkinson's disease.
• Continue the Phase 1/2 study of DNL126 in MPS IIIA.
• Continue screening of participants for Cohort B2 in the TAK-594/DNL593 Phase 1/2 study in participants with FTD-GRN.

Key Dates

Keywords

Denali Therapeutics, Neurodegenerative Diseases, Lysosomal Storage Diseases, Clinical Trials, Biopharmaceutical, Tividenofusp alfa, DNL310, MPS II, Hunter syndrome, DNL126, MPS IIIA, Sanfilippo syndrome, BIIB122/DNL151, Parkinson's disease, SAR443820/DNL788, Multiple Sclerosis, ALS, Amyotrophic Lateral Sclerosis, LRRK2, RIPK1, Collaboration Agreement, Biogen, Sanofi, Takeda, Private Placement, BLA, FDA, CSF HS, Biomarkers